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Available online 31 January 2018Aims: Autoimmune conditions such as rheumatoid arthritis-related interstitial lung disease (RA-ILD) have been
linked to the existence of emphysema in never-smokers.We aimed to quantify emphysema prevalence in RA-ILD
never-smokers and investigate whether combined pulmonary ﬁbrosis and emphysema (CPFE) results in awors-
ened prognosis independent of baseline disease extent.
Methods: RA-ILD patients presenting to the Royal Brompton Hospital (n= 90) and Asan Medical Center (n= 155)
hadCT's evaluated for a deﬁnite usual interstitial pneumonia (UIP)pattern, andvisual extents of emphysemaand ILD.
Results: Emphysema, identiﬁed in 31/116 (27%) RA-ILD never-smokers, was associated with obstructive functional
indices and conformed to a CPFE phenotype: disproportionate reduction in gas transfer (DLco), relative preservation
of lung volumes. Using multivariate logistic regression, adjusted for patient age, gender and ILD extent, emphysema
presence independently associated with a CT-UIP pattern in never-smokers (0.009) and smokers (0.02).
Onmultivariate Cox analysis, following adjustment for patient age, gender, DLco, and a CT-UIP pattern, emphysema
presence (representing the CPFE phenotype) independently associated withmortality in never-smokers (p= 0.04)
and smokers (p b 0.05).
Conclusion: 27% of RA-ILD never-smokers demonstrate emphysema on CT. Emphysema presence in never-smokers
independently associates with a deﬁnite CT-UIP pattern and aworsened outcome following adjustment for baseline
disease severity.od, Mi
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In rheumatoid arthritis-related interstitial lung disease (RA-ILD), the
prevalence of smoking ranges between 38–72% (Kim et al., 2010;
Tsuchiya et al., 2011; Kelly et al., 2014; Antoniou et al., 2013; Saag et
al., 1996; Yunt et al., 2017). Smoking has been implicated in the devel-
opment (Kelly et al., 2014; Saag et al., 1996; Gochuico et al., 2008) and
coarsening of ILD (Antoniou et al., 2013) and is associated with theddlesex HA6 2HW, UK.
d Critical Care Medicine,
88, Olympic-Ro 43-Gil,
c.seoul.kr (J.W. Song).
cess to all the data in the
ublication.
s an open access article underpresence of emphysema on CT at lower pack-year ranges than that
seen in chronic obstructive pulmonary disease (COPD) controls
(Antoniou et al., 2013). A recent large Canadian study demonstrated
that RA patients have a 47% adjusted higher risk of hospitalization for
COPD than the general population, with results maintained following
modelling for potential confounding effects of smoking (McGuire et
al., 2017).
Emphysema has previously been identiﬁed in never-smokers in an
underpowered cohort of patients with rheumatoid lung (8) and in
7.5% of a large cohort of never-smokers with scleroderma-associated
pulmonary ﬁbrosis (13). Autoimmune pathways have been linked to
the development of emphysema in patients with COPD (Zhang et al.,
2014; Feghali-Bostwick et al., 2008; Packard et al., 2013) and may un-
derlie the occurrence of emphysema in never-smokers with ﬁbrosing
lung disease (Antoniou et al., 2013; Antoniou et al., 2015).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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related ILD, emphysema adversely affects prognosis by increasing the
likelihood of developing pulmonary hypertension (PHT) (Cottin et al.,
2011). However, in a contemporary study of IPF patients, combined pul-
monary ﬁbrosis and emphysema (CPFE) was not associated with a
worsened outcome beyond that explained by the baseline CT disease
extents of emphysema and ILD (Jacob et al., 2017).
Prompted by a recent position paper on RA-ILD encouraging future
analyses of cohorts from multiple centres (Doyle et al., 2014), and a
meta-analysis emphasizing the small sample sizes associated with the
majority of prior RA-ILD studies (Assayag et al., 2014), our study exam-
ined two large RA-ILD cohorts to answer three questions. Firstly, we
quantiﬁed emphysema prevalence in never-smokers with RA-ILD. Sec-
ondly, in never-smokers, we examinedwhether thepresence of emphy-
sema links to a deﬁnite usual interstitial pneumonia (UIP) pattern
(Raghu et al., 2011) on CT, identiﬁed as being a poor prognostic maker
in RA-ILD (Kim et al., 2010; Tsuchiya et al., 2011; Kelly et al., 2014;
Yunt et al., 2017; Assayag et al., 2014). Lastly, we investigated whether
CPFE has a worsened prognosis in RA-ILD, over and above the extent of
emphysema and ILD.
2. Methods
2.1. Clinical Data
A retrospective analysis of an ILD database identiﬁed all new consec-
utive patients presenting between January 2007 to July 2014 to the
Royal Brompton Hospital, London, and from May 1995 to May 2015 to
the Asan Medical Center, Seoul. Patients with a diagnosis of RA-ILD as
conﬁrmed on multidisciplinary team review were identiﬁed. The diag-
nosis of rheumatoid arthritis was made according to the American Col-
lege of Rheumatology/European League Against Rheumatism criteria
(Aletaha et al., 2010). Patientswere deﬁned as “ever smokers” following
evaluation of clinical notes if they had smoked at least one cigarette per
day for at least one year.
Approval for this study of clinically indicated CT and pulmonary
function data was obtained from the Institutional Ethics Committee of
the Royal Brompton Hospital and the Institutional Review Board of the
Asan Medical Center, Seoul, Korea and informed patient consent was
not required.
2.2. CT Evaluation
CT and pulmonary function protocols are described in the Supple-
mentary Appendix. Each CT scan was evaluated independently by two
radiologists (GC, JB)with 3 and4 years imaging experience respectively,
blinded to all clinical information. Interstitial CT parameters evaluated
visually on a lobar basis included ground glass densities, reticular opac-
ities, and honeycombing (Jacob et al., 2017).
Emphysema was classiﬁed as being centrilobular and/or paraseptal
and as thin-walled cystic lesions within areas of co-existent ﬁbrosis
(Inomata et al., 2014). Emphysema was further subcategorized into
one of two types: geographically distinct from areas of ﬁbrotic lung
(non-admixed emphysema) and as emphysema lyingwithin areas of ﬁ-
brosis (admixed emphysema) as previously described (Jacob et al.,
2017). The total extent of emphysema was quantiﬁed on a lobar basis
and the proportion of admixed emphysematous lung was recorded.
The percentage of admixed emphysema was derived as follows:
Percent admixed emphysema
¼ total%emphysema x proportion admixedð Þ=100
The percentage of non-admixed emphysema represented the re-
mainder of the scored emphysema. All CT variables were expressed as
a percentage of the total lung volume. Total ILD extent represented
the sum of ground glass opacities, reticulation and honeycombing. Adeﬁnite radiological UIP pattern was deﬁned using the ATS/ERS/JRS/
ALAT consensus statement for IPF (Raghu et al., 2011) and was scored
for each CT by a separate scorer (JJ), with 10 years imaging experience
blinded to all clinical information.
2.3. Consensus Formulation for Visual Scores
Following visual CT scoring, the identiﬁcation of systematic biases in
visual scores was achieved by plotting the spread of differences in pa-
renchymal pattern scores between observers. The most disparate 5%
(two standard deviations) of values were arbitrated by a third scorer
(JJ) as was any disagreement between scorers for the presence of either
emphysema or honeycombing. Identiﬁcation of emphysema in never-
smokers was veriﬁed by the same third scorer (JJ).
2.4. Pulmonary Function Tests
Pulmonary function indices examined in the current study included
forced expiratory volume in one second (FEV1), forced vital capacity
(FVC), the diffusing capacity for carbon monoxide (DLco) and the car-
bon monoxide transfer coefﬁcient (Kco).
3. Statistical Analysis
Data are given asmeanswith standard deviations, or numbers of pa-
tients with percentages where appropriate. Interobserver variation for
visual scores was assessed using the single determination standard de-
viation for continuous variables and as the Kappa statistic for categorical
variables.Meandifferences between groupswere evaluated using a Chi-
squared test for categorical variables or a two-sample t test for paramet-
ric continuous variables, and theMann-WhitneyU test formedians. Sta-
tistical signiﬁcance was evaluated at a value of p b 0.05. Univariate and
multivariate linear regression analyses were used to identify relation-
ships between CT and functional indices. Univariate Cox proportional
hazards analyses identiﬁed variables associated with outcome. Survival
estimation was performed via the Kaplan Meier method. Two-sample
survival comparisons were performed using the Log rank test.
Four main domains were evaluated in the study: i) prevalence of
emphysema in never-smokers, ii) mortality impact of CPFE in never-
smokers, iii) association of emphysemawith honeycombing (and sepa-
rately evaluated as IPF-like and non-IPF-like) in never-smokers, iv) an
associated CPFE functional proﬁle in never-smokers with emphysema.
Analyses performed in never-smokers were compared to parallel anal-
yses in smokers acting as a control group. In all control-group models
(smokers), adjustment was made for patient pack-year history.
Amultivariate Cox proportional hazard model investigated whether
a CPFE phenotype has an independent effect on outcome in never-
smokers after adjusting for baseline disease extent (usingDLco), patient
age, gender, and baseline disease severity (using CT honeycomb pres-
ence). Baseline DLco, was used to adjust for baseline disease extent as
it captures disease secondary to interstitial ﬁbrosis, emphysema and
any associated pulmonary hypertension (Jacob et al., 2017). Baseline
disease severity was measured using a CT deﬁnite UIP pattern as this
has been well recognized as a robust measure of severity in RA-ILD
patients.
A multivariate logistic regression model examined variables that
were associated with the presence of a) honeycombing on CT in
never-smokers and b) an ATS/ERS/JRS/ALAT consensus diagnosis of a
deﬁnite UIP pattern on CT (Raghu et al., 2011). Both associations of CT
honeycombing presence and a deﬁnite UIP pattern on CT were sepa-
rately evaluated in the study to allow consideration of a UIP pattern (ev-
idenced by honeycombing on CT) in RA-ILD, which would not strictly
conform to the agreed deﬁnition of a UIP pattern in IPF, given differ-
ences in disease distribution in RA-ILD (less basal predominant disease,
and more peribronchovascular ﬁbrosis) compared to an IPF-like UIP
pattern (Raghu et al., 2011). Variables inserted into the regression
Table 1
Characteristics of RA-ILD patients with (n = 129 unless stated) and without (n = 116 unless stated) emphysema. Variables examined include: patient demographic details, pulmonary
function indices and visually scored CT parameters. The t-test was used for continuous variables. *Chi-Square test, ^Mann-Whitney U test. Differences inmedian follow up time were cal-
culated using the Log Rank Test. FEV1 = forced expiratory volume in 1 s, FVC = forced vital capacity, DLco = diffusing capacity for carbon monoxide, Kco = carbon monoxide transfer
coefﬁcient, ILD = interstitial lung disease.
Variable Emphysema absent Emphysema present Group comparison
Units are percentage unless stated
Median age (years) 62 63 =0.86^
Male/female (ratio) 25/91 85/44 b0.0001*
Survival (alive/dead) 80/36 55/74 b0.0001*
Never/ever-smokers (ratio) 85/31 31/98 b0.0001*
FEV1% predicted 79.6 ± 21.1 (115) 76.2 ± 20.7 (121) =0.21
FVC % predicted 73.4 ± 18.0 (115) 76.6 ± 21.7 (121) =0.22
DLco % predicted 58.5 ± 19.8 (108) 49.5 ± 20.5 (122) =0.001
Kco % predicted 82.5 ± 17.8 (71) 65.5 ± 17.7 (93) b0.0001
Visual ILD extent 26.0 ± 16.9 28.9 ± 18.5 =0.20
Visual honeycombing extent 2.4 ± 4.2 4.8 ± 8.4 =0.006
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ma presence. Model ﬁt was evaluated using the C-statistic.
Lastly, using multivariate linear regression analyses, we examined
whether never-smokers with emphysema displayed a CPFE lung func-
tional proﬁle, characterized by disproportionate DLco reduction and ar-
tiﬁcially preserved lung volumes. In each model, adjustment was made
for patient age, gender, and baseline ILD extent. All positive logistic re-
gression and proportional hazards models were re-run, adjusting for
the study center. Assumptions of linearity and proportional hazards
were tested by visual inspection of Martingale residuals and scaled
Schoenfeld residuals and were satisﬁed. Statistical analyses were per-
formed with SPSS (IBM SPSS Statistics for Macintosh, Version 20.0.
(IBM. Corp., Armonk, NY, USA).
4. Results
4.1. Demographic Data
90 patients presenting to the Royal Brompton Hospital and 155 pa-
tients presenting to the Asan Medical Center diagnosed with RA-ILD
had vital status completed with no patients lost to follow up. Baseline
differences between the populations at the two institutions are demon-
strated in Supplementary Table 1. A signiﬁcant difference in smoking
rates between patients at the two institutions (p = 0.0003) [Table 1]
was primarily explained by differences in smoking rates between
women: female Asan ex-smokers = 7/88 (8%); female Brompton ex-
smokers = 25/47 (53%)[p b 0.0001]. Smoking rates were similarTable 2
Characteristics of never-smokers (n=116 unless stated) and smokers (n=129 unless stated)w
indices and visually scored CT parameters. The t-test was used for continuous variables. *Chi-S
using the Log Rank Test. FEV1= forced expiratory volume in 1 s, FVC= forced vital capacity, DL
ILD = interstitial lung disease, # = only calculated in patients with emphysema.
Variable Never-smokers
Units: percentages unless stated
Median age (years) 60
Male/female (ratio) 13/103
Survival (alive/dead) 77/39
Median Follow up (months) 75.7 ± 4.2
FEV1% predicted 79.4 ± 21.7 (115)
FVC % predicted 74.1 ± 18.5 (115)
DLco % predicted 58.3 ± 21.0 (111)
Kco % predicted 79.1 ± 18.4 (70)
Visual ILD extent 26.8 ± 17.4
Visual Honeycombing extent 3.2 ± 6.0
Visual Honeycombing presence (Y/N) 71/45
Visual Emphysema extent# 6.5 ± 11.0 (31)
Non-admixed emphysema extent# 2.7 ± 5.5 (31)
Admixed emphysema extent# 3.8 ± 5.8 (31)amongst men in both institutions: male Asan ex-smokers = 61/67
(91%); male Brompton ex-smokers = 36/43 (84%)[p=0.25].
Differences in baseline variables, across both cohorts, for RA-ILD pa-
tients with and without emphysema and between smokers and never-
smokers are shown in Tables 1 and 2 respectively. Variation in visual
CT scores for continuous variables, as measured by the single determi-
nation standard deviation, are shown in Supplementary Table 2.
Kappa values for the two scorers for the presence of emphysema were
0.51. Survival curves for patients with and without honeycombing and
with and without a deﬁnite UIP pattern on CT are shown in Fig. 1a
and b respectively.
Across the entire study population, the presence of visually scored
emphysema was associated with obstructive FEV1/FVC values on spi-
rometry (β=−7.26, 95%CI−11.48,−3.04, p = 0.001) following ad-
justment for patient age, gender and baseline ILD extent. When
quantiﬁed as percentages of the lung, emphysema lying distant to ﬁ-
brotic lung (β=−0.75, 95%CI−0.96,−0.54, p b 0.0001) and emphyse-
ma admixed within ﬁbrotic lung (β=−0.54, 95%CI−0.96,−0.12, p=
0.01) were also associated with obstructive values when inserted sepa-
rately into the same models adjusted for patient age, gender, and base-
line ILD extent.
Across the entire study population, the presence of visually scored
honeycombing was associated with restrictive FEV1/FVC values on spi-
rometry (Supplementary Table 3) following adjustment for patient age,
gender and visual extents of reticular opacities and total emphysema.
Whilst reticular opacities also demonstrated restrictive FEV1/FVC
values, emphysema extent demonstrated obstructive FEV1/FVC valuesith RA-ILD. Variables examined include: patient demographic details, pulmonary function
quare test, ^Mann-Whitney U test. Differences in median follow up time were calculated
co=diffusing capacity for carbonmonoxide, Kco= carbonmonoxide transfer coefﬁcient,
Smokers Group comparison
65 =0.01^
97/32 b0.0001*
58/71 =0.001*
80.5 ± 9.0 =0.98
76.4 ± 20.2 (121) =0.27
76.0 ± 21.4 (121) =0.47
49.5 ± 19.5 (119) =0.001
68.2 ± 19.3 (94) =0.0003
28.2 ± 18.2 =0.55
4.2 ± 7.5 =0.26
71/58 =0.33*
14.4 ± 15.1 (98) =0.008
8.5 ± 12.2 (98) =0.01
5.9 ± 6.2 (98) =0.08
Fig. 1.KaplanMeier survival curves in subgroups of patients with rheumatoid arthritis related interstitial lung disease. a. KaplanMeier survival curveswere signiﬁcantly different between
RA-ILD patientswith honeycombing on CT (green, n=142, restrictedmean survival=91.0±11.3) and RA-ILD patientswithout anyhoneycombing onCT (blue, n=103, restrictedmean
survival = 136.1 ± 10.0). Log rank test p b 0.0001. b. Kaplan Meier survival curves were signiﬁcantly different between RA-ILD patients with a deﬁnite UIP pattern on CT (green, n= 74,
restricted mean survival = 73.3 ± 9.2), and RA-ILD patients without a deﬁnite UIP pattern on CT (blue, n = 171, restricted mean survival = 141.9 ± 11.7 months). Log rank test p =
0.0002. c. Kaplan Meier survival curves were signiﬁcantly different between RA-ILD patients without any emphysema on CT (blue, n = 116, restricted mean survival = 161.7 ± 13.6),
and RA-ILD patients with emphysema scored visually on CT (green, n = 129, restricted mean survival = 75.5 ± 7.1). Log rank test p b 0.0001. d. Kaplan Meier survival curves of RA-
ILD patients that were never-smokers (blue; n = 116, restricted mean survival = 129.9 ± 9.3) versus smokers (green; n = 129, restricted mean survival = 87.0 ± 11.5). Log rank
test p = 0.0001.
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of patients with emphysema on CT (Supplementary Table 3).
4.2. Emphysema Presence in Never-Smokers
Emphysema was present on CT in 31/116 (27%, 95% conﬁdence in-
terval = 0.19–0.36) of never-smoking RA-ILD patients compared to
98/129 (76%) control smokers with RA-ILD (p b 0.0001). In never-
smokers, emphysema was present in lung regions distant from pulmo-
nary ﬁbrosis (non-admixed) in 30/31 cases. Emphysema was also
admixed within areas of pulmonary ﬁbrosis in 25/31 cases. In one
never-smoker, emphysema was admixed with ﬁbrosis but was not
present in non-ﬁbrotic areas.
When all patients with emphysema were examined, never-smokers
were found to have less extensive emphysema than smokers (p =
0.008)[Table 2]. Emphysema occurring separate to ﬁbrotic regions was
less extensive in never-smokers than smokers (p = 0.01), and wastypically distributed in the upper lobes of the lungs. The proportion of
total non-admixed emphysema that was present in the upper lobes
did not vary between smokers and never-smokers (p = 0.96). In pa-
tients with non-admixed emphysema, coexisting centrilobular and
paraseptal emphysema was more common in smokers 71/97 (73%)
than never-smokers 11/30 (37%)[p = 0.0003]. In patients with either
centrilobular or paraseptal emphysema, paraseptal emphysema 13/30
(43%) was more common than centrilobular emphysema 6/30 (20%)
in never smokers, and smokers (paraseptal emphysema: 23/97[24%];
centrilobular emphysema: 3/97 [3%]). Thin walled cystic lesions
(Inomata et al., 2014) were more common in smokers 14/97 (14%)
than never-smokers 1/30 (3%)[p = 1.00] with non-admixed emphyse-
ma. In cases where thin walled cystic lesions were seen, centrilobular
and paraseptal emphysema was always present. Admixed emphysema
was predominantly identiﬁed in the lung bases and of similar extent
in smokers and never-smokers (p=0.08). The resultsweremaintained
following adjustment for total emphysema and ILD extents.
Table 3
Univariate Cox regression analysis demonstrating mortality in never-smokers according
to demographic indices (topwhite), visually derivedHRCT indices (light grey), pulmonary
function tests (dark grey). ILD= Interstitial lung disease, FVC= forced vital capacity, DLco
= diffusing capacity for carbon monoxide, Kco = Carbon monoxide transfer coefﬁcient.
Variable
(Units are percentage unless
speciﬁed)
Patient
number
Hazard
ratio
95.0%
conﬁdence
interval
P value
Lower Upper
Age (years) 116 1.05 1.02 1.08 0.001
Gender (M = 1, F = 0) 116 1.49 0.57 3.84 0.41
Visual CT scores
ILD extent 116 1.03 1.02 1.05 b0.0001
Honeycombing extent 116 1.08 1.05 1.12 b0.0001
Honeycombing presence 116 2.90 1.36 6.21 0.006
Non-admixed emphysema 116 1.08 1.02 1.15 0.009
Admixed emphysema 116 1.11 1.04 1.18 0.002
Total emphysema 116 1.05 1.02 1.08 0.003
Emphysema presence 116 1.51 0.78 2.95 0.23
Emphysema N 5% 116 2.34 0.88 6.17 0.09
Emphysema N 10% 116 6.84 2.00 23.42 0.002
Pulmonary Function Tests
FVC 115 0.97 0.95 0.99 0.009
DLco 111 0.98 0.96 1.00 0.02
Kco 70 0.97 0.95 1.00 0.03
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Univariate Cox regression analysis demonstrated that increasing
emphysema extent, as well as both emphysema subtypes (non-
admixed and admixed) were strongly associated with mortality in
never-smokers (Table 3). Functional indices did not strongly associate
with outcome in never-smokers (Table 3) when compared to smokers
(Supplementary Table 4). Outcome differences between patients with
and without emphysema and between never-smokers and smokers
are shown in Fig. 1c and d respectively.
On multivariate Cox regression analysis, after adjusting for patient
age, gender, baseline disease extent using DLco, and a deﬁnite UIP pat-
tern on CT, in never-smokers (and separately in smokers), the presence
of emphysema (indicating a CPFE phenotype) was independently asso-
ciated withmortality (Table 4). All models wasmaintained after adjust-
ment for study center.
4.4. Associations of Honeycombing Presence on CT
In never-smokers, patient age, gender, ILD extent and emphysema
presence were inserted into a multivariate logistic regression model
(Table 5). The presence of emphysema (p= 0.005) was independently
associated with the presence of honeycombing on CT (Model C-statistic
= 0.71). The ﬁnding, though weaker in strength, was maintained in
smokers (p = 0.02), after adjusting for smoking pack year history
(Model C-statistic = 0.78). Emphysema presence also linked to a deﬁ-
nite UIP pattern on CT (Table 5) in never-smokers (model C-statistic
= 0.75) and smokers (model C-statistic = 0.77) when using the same
logistic regression models.
The extent of ILD, whilst strongly associated with honeycombing
presence in smokers (p= 0.001), did not associate with honeycombing
presence in never-smokers and demonstrated no linkage to a deﬁnite
UIP pattern in never-smokers and smokers (Table 5). All models were
maintained after adjustment for study center.
4.5. Functional Effects of Emphysema in RA-ILD Never-Smokers
In never-smokers, a classic CPFE functional proﬁle of a dispropor-
tionate reduction in DLco and artiﬁcially preserved lung volumes was
not identiﬁed and was thought to be a consequence of the limited ex-
tents of emphysema in never-smokers (of the 81 study patients with
over 5% emphysema, only 10/81 [12%] were never-smokers). When
the functional effects of emphysema presence were examined across
the whole study population, a CPFE functional proﬁle was identiﬁed
with results maintained at a 5% emphysema threshold (Supplementary
Table 5). Across the entire study population, emphysema lying distant
to ﬁbrotic lung (non-admixed) demonstrated an independent negative
association with DLco and Kco. In a similar adjustedmodel, an indepen-
dent negative association was identiﬁed between admixed emphysema
and Kco, but not DLco (Supplementary Table 6).
5. Discussion
Our study has identiﬁed several ﬁndings in patients with RA-ILD.
Firstly, across two independent cohorts of patients, emphysema was
identiﬁed in 27% of never-smokers. Secondly, in never-smokers, the
presence of emphysema was independently associated with the pres-
ence of honeycombing on CT and a CT UIP pattern. Lastly, we demon-
strated that the presence of emphysema, representing the CPFE
phenotype, is independently associated with a worsened outcome in
never-smokers and smokers with RA-ILD following adjustment for
baseline disease severity.
Our study represents a detailed multicenter evaluation of emphyse-
ma and smoking burden in patients with RA-ILD. The primary study aim
emerged from limited data in previous analyses of ILD cohorts, whereby
emphysema had been identiﬁed in life-long never-smokers with IPF(Jacob et al., 2017), RA-ILD (Antoniou et al., 2013), and scleroderma
(Antoniou et al., 2015). Since the cardinal question posed by our study
revolved around the prevalence of emphysema, to avoid biases in em-
physema characterization, all scorers were blinded to all clinical details.
Reassuringly, the interobserver agreement for the presence of emphy-
sema in our analyses was similar to previous CT descriptions of emphy-
sema in patients with RA-ILD (Antoniou et al., 2013), scleroderma
(Antoniou et al., 2015), and IPF (Jacob et al., 2017).
Four separate observations suggested that the scorers had avoided
themisclassiﬁcation of non-emphysematous lung as emphysema. First-
ly, emphysema was scored more extensively in ever-smokers than
never-smokers and proportions of emphysema separate to and occur-
ring within ﬁbrotic lung were similar in both patient groups. Secondly,
in all but one case, when admixed emphysema was identiﬁed, emphy-
sema was identiﬁed lying separate to ﬁbrotic lung and was predomi-
nantly distributed within the upper lobes of the lung. Thirdly,
parenchyma classiﬁed as both non-admixed and admixed emphysema
was associated with obstructive functional indices. Furthermore, across
the whole study population, the CPFE functional proﬁle in RA-ILD mir-
rored the disproportionate reduction in gas transfer occurring with a
relative preservation of lung volumes that has come to deﬁne the func-
tional CPFE phenotype in IPF (Jacob et al., 2017; Ryerson et al., 2013;
Cottin et al., 2005; Mejía et al., 2009; Bodlet et al., 2013; Mura et al.,
2006). Lastly, honeycombing, which represents the CT pattern most
likely to be confused with emphysema, was associated with restrictive
functional indices when analyzed alongside emphysema extent which
maintained its association with obstructive functional indices.
The presence of emphysema in 27% (95% conﬁdence interval =
0.19–0.36) of never-smoker RA-ILD patients, whilst reinforcing obser-
vations in IPF (15% emphysema prevalence in never-smokers; mea-
sured using contiguous 1.0 mm CT images) (Jacob et al., 2017) and
scleroderma (7% emphysema prevalence in never-smokers; measured
using 1.5–3.0mm thickness axial CT imageswith a 10mmgap between
sections) (Antoniou et al., 2015) was greater than that previously re-
ported in patients with ﬁbrosing lung diseases.
A study by Antoniou et al (Antoniou et al., 2013) identiﬁed emphy-
sema in 2/35 (6%) (Antoniou et al., 2013) never-smokers with RA-ILD,
and in 22/46 (48%) of smokers with RA-ILD. The comparatively low
prevalence of emphysema in never-smokers in the RA-ILD and sclero-
derma studies of Antoniou et al (Antoniou et al., 2013; Antoniou et al.,
2015) are likely to reﬂect fundamental differences in HRCT acquisition
technique. The smaller RA-ILD study population of Antoniou et al
Table 4
Multivariate Cox proportional hazards regressionmodels associatedwithmortality in never-smokers (Model 1) and smokers (Model 2) with RA-ILD, following correction for patient age,
gender, a CT deﬁnite usual interstitial pneumonia (UIP) pattern and baseline disease extent using DLco (diffusing capacity for carbon monoxide). Unadjusted hazard ratios are shown in
brackets.
Multivariate Model Baseline severity and emphysema models Hazard ratio
((unadj), adj)
95.0% conﬁdence interval P value
Lower Upper
Model 1 Age (1.05) 1.06 1.02 1.09 0.003
Gender (1.49) 0.86 0.29 2.55 =0.78
DLco (0.98) 0.98 0.96 1.00 =0.02
Emphysema presence (1.51) 2.30 1.02 5.16 =0.04
CT deﬁnite UIP pattern (1.71) 1.54 0.72 3.32 =0.27
Model 2 Age (1.04) 1.04 1.01 1.07 0.006
Gender (1.35) 0.85 0.44 1.66 0.64
DLco (0.97) 0.97 0.95 0.98 b0.0001
Emphysema presence (2.59) 2.16 1.01 4.62 =0.047
CT deﬁnite UIP pattern (2.26) 2.13 1.24 3.65 =0.006
308 J. Jacob et al. / EBioMedicine 28 (2018) 303–310(Antoniou et al., 2013), was evaluated using 1.5–3.0 mm thickness axial
CT slices acquired at −30 mm intervals. Accordingly, mild extents of
emphysema in the RA-ILD (Antoniou et al., 2013) and scleroderma
(Antoniou et al., 2015) studies may have been missed on individual CT
series when compared to the 1mm thickness slices acquired volumetri-
cally in the Brompton population and the 10mm intervals in the Asan
population.
The presence of emphysema in never-smokers, though limited in
extent and quantiﬁed in a discrete population (31/116 patients), was in-
dependently associated with both the presence of honeycombing on CT
and a deﬁnite CT UIP pattern (Raghu et al., 2011). Whilst passive
smoking is one explanation for emphysema in never-smokers, the
much higher prevalence of emphysema in never-smokers in the current
study, when compared to never-smoker IPF patients (Jacob et al., 2017)
who are on averagemuch older and far more likely to be exposed to the
effects of passive smoking, suggests that passive smoking alone cannot
be the sole explanation for the presence of emphysema in never-
smokers with RA-ILD.
Several independent reports have demonstrated linkages between
RA and COPD prevalance (McGuire et al., 2017; Bieber et al., 2013;
Shen et al., 2014) and RA and COPD hospitalization (McGuire et al.,
2017; Shen et al., 2014). There ﬁndings argue strongly for common
shared, automimmue pathways (Zhang et al., 2014; Feghali-Bostwick
et al., 2008; Packard et al., 2013) that may activate protein citrullination
(Rocha-Muñoz et al., 2015;Makrygiannakis et al., 2008; Rangel-Moreno
et al., 2006; Scally et al., 2013), oxidative stresses (Vuorinen et al., 2008;
Volonte et al., 2009), andmatrix remodeling (Zandvoort et al., 2008) allTable 5
Multivariate logistic regression models associated with a) the presence of honeycombing on CT
pulmonary ﬁbrosis, ILD = interstitial lung disease extent. Unadjusted odds ratios are shown in
Smoking status Dependent variable Variable
Never smoker Honeycombing presence
(Yes = 1, No = 0)
Age (years)
Gender (Male = 1)
ILD extent (%)
Emphysema presence (Yes =
Smoker Honeycombing presence
(Yes = 1, No = 0)
Age (years)
Gender (Male = 1)
ILD extent (%)
Emphysema presence (Yes =
Smoking pack year history
Never smoker IPF Deﬁnite CT UIP pattern
(Yes = 1, No = 0)
Age (years)
Gender (Male = 1)
ILD extent (%)
Emphysema presence (Yes =
Smoker IPF Deﬁnite CT UIP pattern
(Yes = 1, No = 0)
Age (years)
Gender (Male = 1)
ILD extent (%)
Emphysema presence (Yes =
Smoking pack year historyof which have been implicated in the etiology of both emphysema and
ﬁbrosis.
The presence of emphysema was linked to an adverse outcome in
both never-smokers and smokers with RA-ILD and runs counter to a re-
cent report in IPF patients where, following analogous correction for
baseline disease extent, CPFEwas shown to have no addedmortality ef-
fect in IPF (Jacob et al., 2017). Patients with IPF have more extensive ﬁ-
brotic disease, and die rapidly as a consequence of their lung ﬁbrosis. In
patients with RA-ILD however, a more limited extent of ILD, and a lon-
ger disease coursemay result in emphysema and the impact of smoking
related co-morbidities having a greater inﬂuence on patient outcome.
The lack of a linkage between ILD extent on CT and CT honeycombing
presence/deﬁnite CT UIP pattern (Raghu et al., 2011) may be explained
by RA-ILD patients with extensive disease that have a non-speciﬁc in-
terstitial pneumonia rather than a UIP pattern of ﬁbrosis.
There were limitations to the current study. We examined two dis-
tinct populations of patients with RA-ILD and identiﬁed fundamental
demographic differences between the populations, such as the low
rate of smoking within the Korean female population when compared
to British women with RA-ILD. Yet, we would argue that the use of dis-
parate RA-ILD populations are a fundamental strength of our study and
confer a robustness to our results when cardinal observations such as
the occurrence of emphysema in never-smokers are replicated across
both study cohorts. The relatively small sample size of 116 never-smok-
er RA-ILD patients in our study resulted in the relatively wide 95% con-
ﬁdence intervals for the presence of emphysema in never-smokers.
Whilst our study remains one of the largest detailed examinations ofb) an IPF-like deﬁnite UIP pattern on CT, in never-smokers and smokers. IPF = idiopathic
brackets.
Odds ratio
((unadj)/adj)
95.0% conﬁdence interval P value
Lower Upper
(1.04) 1.06 1.02 1.10 0.005
(2.30) 0.90 0.19 4.21 0.89
(1.01) 1.01 0.99 1.03 0.42
1) (3.53) 5.05 1.64 15.56 0.005
(1.03) 1.03 0.99 1.08 0.17
(2.59) 2.04 0.78 5.30 0.15
(1.05) 1.04 1.02 1.07 0.001
1) (3.46) 3.23 1.21 8.62 0.02
(1.02) 1.01 0.99 1.03 0.29
(1.06) 1.09 1.04 1.14 0.0004
(0.70) 0.27 0.06 1.32 0.11
(0.98) 0.97 0.94 1.00 0.05
1) (1.81) 4.36 1.44 13.20 0.009
(1.01) 0.99 0.95 1.04 0.79
(9.66) 7.61 1.62 35.79 0.01
(1.02) 1.01 0.98 1.03 0.66
1) (3.92) 4.64 1.24 17.36 0.02
(1.02) 1.02 1.00 1.04 0.06
309J. Jacob et al. / EBioMedicine 28 (2018) 303–310emphysema extent on CT in RA-ILD patients, larger multicentred stud-
ies would be important to validate our observations.
As we examined a respiratory and not a rheumatological database
for our study, we were limited with regard to the serological informa-
tion we were able to analyze. We had no information on patient symp-
tom duration (both respiratory and rheumatological) prior to
presentation to either tertiary center, or information on the cause of
death in the study population. Furthermore, as tertiary care centers,
we do not always receive comprehensive information regarding patient
management at local primary or secondary base care centres, where
treatment regimens such as dose and duration of steroid treatment,
and choice of steroid sparing agents can vary widely. As an a priori de-
cision, we intentionally chose not to try to quantify steroid dosages at
the time of presentation with RA-ILD as many patients may have had
RA pre-existing for some years before the development of symptomatic
ILD. During this pre-symptomatic period, patients may have received
steroids and steroid sparing agents for some time, with the result that
knowledge of steroid use at a single point in time, or for the duration
of symptomatic ILD, is likely to have only provided part of the patients
treatment proﬁle, and its effect on lung disease.
In conclusion, our study has demonstrated that 27% of RA-ILD pa-
tients that have never-smoked have emphysema visible on CT. We
have shown that in both never-smokers and smokers, the presence of
emphysema independently associates with the presence of
honeycombing on CT and the negatively-prognostic CT-UIP pattern.
We have also demonstrated that CPFE is associated with a worsened
outcome in RA-ILD, following correction for baseline disease severity,
when compared patients without emphysema.
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